Cervical intraepithelial neoplasia: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(61 intermediate revisions by 6 users not shown)
Line 1: Line 1:
'''For patient information, please click [[Cervical dysplasia (patient information)|here]]'''
__NOTOC__
__NOTOC__
{{SI}}                                                                     
{{CMG}} {{AE}} {{MV}}
{{SK}} CIN; Cervical interstitial neoplasia; Cervical dysplasia; Cervical interstitial neoplasia
==Overview==
'''Cervical intraepithelial neoplasia'''  (also known as '''cervical dysplasia''' and '''CIN'''), is the potentially [[premalignant]] transformation and abnormal growth ([[dysplasia]]) of [[squamous]] cells on the surface of the [[cervix]]. Cervical intraepithelial neoplasia was first discovered by Dr. Georgios Nikolaou Papanikolaou, a Greek [[pathologist]], in 1927. There are 4 [[cytological]] classifications for cervical intraepithelial neoplasia: Bethesda system, Papanicolaou classification, CIN nomenclature, and dysplasia nomenclature.  The most common [[cytological]] classification systems for cervical intraepithelial neoplasia is the Bethesda and CIN nomenclature.  Cervical intraepithelial neoplasia may be classified according to Bethesda system by [[cytology]] description into 3 subtypes: atypical squamous cells, low grade squamous intraepithelial lesion (LGSIL or LSIL), and high grade squamous intraepithelial lesion (HGSIL or HSIL).  The [[pathogenesis]] of cervical intraepithelial neoplasia is characterized by the [[premalignant]] transformation and abnormal growth of [[Squamous cell|squamous cells]] on the surface of the [[cervix]]. The presence of [[human papillomavirus]] ([[Human papillomavirus|HPV]]) has a crucial role in the [[pathogenesis]] of cervical intraepithelial neoplasia. The infection o[[Human papillomavirus|f human papillomavirus (HPV)]] leads to the first precursor lesion of cervical intraepithelial neoplasia, also known as the [[koilocyte]], which is a [[Squamous cell|squamous epithelial cell]] that has undergone a number of structural changes. [[Surgery]] is the mainstay of therapy for cervical intraepithelial neoplasia. According to the American Society for Colposcopy and Cervical Pathology guidelines, indications for [[Ablation|ablative surgery]] among patients with cervical intraepithelial neoplasia should include: persistent low-grade cervical intraepithelial neoplasia, cervical intraepithelial neoplasia grade II and grade III. Common surgical procedures for cervical intraepithelial neoplasia, include [[cryocautery]], [[electrocautery]], [[Laser|laser cautery]], and [[cervical conization]].
==Historical Perspective==
*Cervical intraepithelial neoplasia was first discovered by Dr. Georgios Nikolaou Papanikolaou, a Greek [[pathologist]], in 1927.<ref name="wiki">Georgios Nikolaou Papanikolaou Wikipedia. https://en.wikipedia.org/wiki/Georgios_Papanikolaou Accessed on March 29, 2016</ref>
*In 1928, the first [[Screening (medicine)|screening]] was developed by Aurel Babeș, a Romanian [[pathologist]] to [[diagnose]] cervical intraepithelial neoplasia.<ref name="wiki">Aurel Babes. Wikipedia https://en.wikipedia.org/wiki/Aurel_Babe%C8%99. Accessed on March 29, 2016</ref>
*In 1980, [[human papillomavirus]] ([[HPV]]) was first identified in the [[pathogenesis]] of cervical intraepithelial neoplasia.<ref name="pmid23399794">{{cite journal |vauthors=Herfs M, Crum CP |title=Laboratory management of cervical intraepithelial neoplasia: proposing a new paradigm |journal=Adv Anat Pathol |volume=20 |issue=2 |pages=86–94 |year=2013 |pmid=23399794 |doi=10.1097/PAP.0b013e3182862aab |url=}}</ref>
*In 1988, the Bethesda system classification method was introduced to categorize [[histopathological]] findings of cervical intraepithelial neoplasia according to degrees of severity.
==Classification==
*Cervical intraepithelial neoplasia has 4 [[cytological]] classifications: Bethesda system, Papanicolaou classification, CIN nomenclature, and [[dysplasia]] nomenclature.
*The most common classification systems for cervical intraepithelial neoplasia is the Bethesda and CIN nomenclature.
*Cervical intraepithelial neoplasia may be classified according to Bethesda  system by [[cytology]] description into 3 subtypes:
:*Atypical [[Squamous cell|squamous cells]]
::*Undetermined significance (ASC-US)
:*Low grade squamous intraepithelial lesion (LGSIL or LSIL)
:*High grade squamous intraepithelial lesion (HGSIL or HSIL)
*Cervical intraepithelial neoplasia may be classified according to CIN nomenclature by [[histological]] severity into 3 subtypes:
:*Cervical intraepithelial neoplasia I (CIN I)
:*Cervical intraepithelial neoplasia II (CIN II)
:*Cervical intraepithelial neoplasia III (CIN III)
*Cervical intraepithelial neoplasia may be classified according to Papanicolau by [[cytology]] description into 5 subtypes:
:*Class I: absence of atypical or abnormal cells
:*Class II: atypical [[cytology]], but no evidence of [[malignancy]]
:*Class III: [[cytology]] suggestive of, but not conclusive for, [[malignancy]]
:*Class IV: [[cytology]] strongly suggestive of [[malignancy]]
:*Class V: [[cytology]] conclusive for [[malignancy]]
*Cervical intraepithelial neoplasia may be classified according to [[dysplasia]] nomenclature by [[cytology]] description into 5 subtypes:
:* Negative
:* Squamous [[atypia]]
:* Mild [[dysplasia]]
:* Moderate [[dysplasia]]
:* Severe [[dysplasia]]
:* [[Carcinoma in situ|Carcinoma]]
*Other variants of cervical intraepithelial neoplasia include [[carcinoma in situ]], typical [[Glandular|glandular cells]] not otherwise specified, and invasive [[carcinoma]].
==Pathophysiology==
*The [[pathogenesis]] of cervical intraepithelial neoplasia is characterized by the [[premalignant]] transformation and abnormal growth of [[Squamous cell|squamous cells]] on the surface of the [[cervix]].<ref name="pmid9602680">{{cite journal |vauthors=Arends MJ, Buckley CH, Wells M |title=Aetiology, pathogenesis, and pathology of cervical neoplasia |journal=J. Clin. Pathol. |volume=51 |issue=2 |pages=96–103 |year=1998 |pmid=9602680 |pmc=500501 |doi= |url=}}</ref>
*Cervical intraepithelial neoplasia arises from cells localized in the ectoendocervical [[Transformation zone|squamocolumnar  junction]] (also known as the "[[transformation zone]]") of the [[cervix]] persistently infected with the  [[human papillomavirus]] ([[Human papillomavirus|HPV]]).
*The presence of [[human papillomavirus]] ([[Human papillomavirus|HPV]]) subtypes 16 and 18 plays an essential role in the [[pathogenesis]] of [[cervical cancer]] and the [[pathogenesis]] of cervical intraepithelial neoplasia.<ref name="pmid18701931">{{cite journal |vauthors=Braaten KP, Laufer MR |title=Human Papillomavirus (HPV), HPV-Related Disease, and the HPV Vaccine |journal=Rev Obstet Gynecol |volume=1 |issue=1 |pages=2–10 |date=2008 |pmid=18701931 |pmc=2492590 |doi= |url=}}</ref><ref name="pmid26685704">{{cite journal |vauthors=Skinner SR, Wheeler CM, Romanowski B, Castellsagué X, Lazcano-Ponce E, Del Rosario-Raymundo MR, Vallejos C, Minkina G, Pereira Da Silva D, McNeil S, Prilepskaya V, Gogotadze I, Money D, Garland SM, Romanenko V, Harper DM, Levin MJ, Chatterjee A, Geeraerts B, Struyf F, Dubin G, Bozonnat MC, Rosillon D, Baril L |title=Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study |journal=Int. J. Cancer |volume=138 |issue=10 |pages=2428–38 |date=May 2016 |pmid=26685704 |pmc=4787275 |doi=10.1002/ijc.29971 |url=}}</ref>
*The first precursor lesion of cervical intraepithelial neoplasia is the [[koilocyte]], which is a [[Squamous cell|squamous epithelial cell]] that has undergone a number of structural changes (these usually occur as a result of [[infection]] by [[human papillomavirus]]).<ref name="pmid18688031">{{cite journal |vauthors=Krawczyk E, Suprynowicz FA, Liu X, Dai Y, Hartmann DP, Hanover J, Schlegel R |title=Koilocytosis: a cooperative interaction between the human papillomavirus E5 and E6 oncoproteins |journal=Am. J. Pathol. |volume=173 |issue=3 |pages=682–8 |date=September 2008 |pmid=18688031 |pmc=2527066 |doi=10.2353/ajpath.2008.080280 |url=}}</ref>
*On [[gross pathology]], there are no characteristic findings of cervical intraepithelial neoplasia.
*On [[microscopic]] [[histopathological]] analysis, findings of cervical intraepithelial neoplasia depends on the [[lesion]] grade.
*The table below summarizes the [[histopathological]] findings of cervical intraepithelial neoplasia according to the [[lesion]] grade.
{| class="wikitable"
! align="center" style="background:#4479BA; color: #FFFFFF;" + | Cytologic findings <br> <SMALL>Lesion grade</SMALL>
! align="center" style="background:#4479BA; color: #FFFFFF;" + | Histologic changes <br><SMALL>Bethesda system</SMALL>
! align="center" style="background:#4479BA; color: #FFFFFF;" + | Description
! align="center" style="background:#4479BA; color: #FFFFFF;" + | Microscopic findings
|-
| '''CIN I'''
Cervical intraepithelial neoplasia I
|
*Low-grade lesion squamous intraepithelial lesion ('''LGSIL''')
|
*Mild [[dysplasia]], or abnormal cell growth
*Presence of [[Koilocyte|koilocytes]]
*Typical cellular changes are usually in the lower third of the [[epithelium]]
| [[Image:Cervical_intraepithelial_neoplasia_(2)_koilocytosis.jpg‎|center|100px]]
|-
| '''CIN II'''
Cervical intraepithelial neoplasia II
|
*High-grade lesion squamous intraepithelial lesion ('''HGSIL''')
|
*Moderate [[dysplasia]]
*Basal two-thirds of the [[epithelium]] is usually involved
*Preservation of [[epithelial]] maturation
| [[Image:100px-Cervical_intraepithelial_neoplasia_(3)_CIN2.jpg‎|center|100px]]
|-
| '''CIN III'''
Cervical intraepithelial neoplasia III
|
*High-grade lesion squamous intraepithelial lesion ('''HGSIL''')
|
*Severe atypical cellular changes
*Greater than two-thirds of the [[epithelial]] thickness is usually involved
*Also known as [[Carcinoma in situ]]
| [[Image:451px-Cervical_intraepithelial_neoplasia_(4)_CIN3.jpg‎|center|100px]]
|}


'''For patient information on Cervical Cancer, click [[Cervical cancer (patient information)|here]]'''
===Molecular Pathogenesis===
*The progression of cervical intraepithelial neoplasia usually involves the [[viral replication]] of the [[human papillomavirus]] ([[HPV]]) following the [[mutation]] of [[proteins]] E6/E7, resulting in the [[overexpression]] of these oncoproteins.
*The overexpression of these oncoproteins generates a deficient [[Cell (biology)|cell]] replication and excessive [[cell growth]].
*The [[E6 - protein|E6/E7 proteins]] inactivate two [[Tumor suppressor genes|tumor suppressor proteins]], [[p53]] (inactivated by E6) and pRb (inactivated by E7).
*The [[viral]] [[oncogenes]] E6 and E7 modify the cell cycle so as to retain the differentiating host [[keratinocyte]] in a state that is favorable to the [[amplification]] of [[viral]] [[genome]] replication and consequent late [[gene expression]].
*E6 in association with host E6-associated protein, which has [[ubiquitin ligase]] activity, acts to ubiquitinate [[p53]], leading to its proteosomal degradation.
*E7 (in oncogenic HPVs) acts as the primary transforming protein.
*E7 competes for [[retinoblastoma]] protein (pRb) binding, freeing the [[transcription factor]] E2F to transactivate its targets, thus pushing the [[cell cycle]] forward.


'''For patient information on Cervical Dysplasia, click [[Cervical dysplasia (patient information)|here]]'''
==Causes==


{{Cervical intraepithelial neoplasia}}
*The most important cause of cervical intraepithelial neoplasia is [[human papillomavirus]] ([[HPV]])
{{CMG}}
:*Low-risk type or non-[[oncogenic]], include:
::*Subtypes 16,18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 69, 82
:*High-risk type or [[oncogenic]], include:
::*Subtypes 6, 11, 40, 42, 43, 44, 54, 61, 72, 81


==[[Cervical intraepithelial neoplasia overview|Overview]]==
==Differentiating Cervical Intraepithelial Neoplasia from Other Diseases==
*Cervical intraepithelial neoplasia must be differentiated from other diseases that cause [[Vaginal bleeding|abnormal vaginal bleeding]], [[dyspareunia]], and [[Vaginal discharge|abnormal vaginal discharge]], such as:
:*[[Cervicitis]]
:*[[Vaginal cancer]]
:*[[Vaginitis]]
:*[[Extramammary Paget's disease]]
==Epidemiology and Demographics==
===Prevalence===
*The [[prevalence]] of cervical intraepithelial neoplasia I (CIN I) is approximately 54 cases per 100,000 individuals in the United States.<ref name="pmid17327523">{{cite journal |vauthors=Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE |title=Prevalence of HPV infection among females in the United States |journal=JAMA |volume=297 |issue=8 |pages=813–9 |year=2007 |pmid=17327523 |doi=10.1001/jama.297.8.813 |url=}}</ref>
*The [[prevalence]] of cervical intraepithelial neoplasia II (CIN II) is approximately 255 cases per 100,000 individuals in the United States.<ref name="pmid17327523">{{cite journal |vauthors=Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE |title=Prevalence of HPV infection among females in the United States |journal=JAMA |volume=297 |issue=8 |pages=813–9 |year=2007 |pmid=17327523 |doi=10.1001/jama.297.8.813 |url=}}</ref>
*The [[prevalence]] of cervical intraepithelial neoplasia III (CIN III) is approximately 141 cases per 100,000 individuals in the United States.<ref name="pmid17327523">{{cite journal |vauthors=Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE |title=Prevalence of HPV infection among females in the United States |journal=JAMA |volume=297 |issue=8 |pages=813–9 |year=2007 |pmid=17327523 |doi=10.1001/jama.297.8.813 |url=}}</ref>
*The [[prevalence]] of [[Carcinoma|invasive carcinoma]] is approximately 24 cases  per 100,000 individuals in the United States.<ref name="pmid17327523">{{cite journal |vauthors=Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE |title=Prevalence of HPV infection among females in the United States |journal=JAMA |volume=297 |issue=8 |pages=813–9 |year=2007 |pmid=17327523 |doi=10.1001/jama.297.8.813 |url=}}</ref>


==[[Cervical intraepithelial neoplasia historical perspective|Historical Perspective]]==
===Incidence===
*The [[incidence]] of cervical intraepithelial neoplasia I (CIN I) is 160 cases per 100,000 individuals per year in the United States.<ref name="pmid20040833">{{cite journal |vauthors=Henk HJ, Insinga RP, Singhal PK, Darkow T |title=Incidence and costs of cervical intraepithelial neoplasia in a US commercially insured population |journal=J Low Genit Tract Dis |volume=14 |issue=1 |pages=29–36 |year=2010 |pmid=20040833 |doi=10.1097/LGT.0b013e3181ac05e9 |url=}}</ref>
*The [[incidence]] of cervical intraepithelial neoplasia II (CIN II) is 120 cases per 100,000 individuals per year in the United States.<ref name="pmid20040833">{{cite journal |vauthors=Henk HJ, Insinga RP, Singhal PK, Darkow T |title=Incidence and costs of cervical intraepithelial neoplasia in a US commercially insured population |journal=J Low Genit Tract Dis |volume=14 |issue=1 |pages=29–36 |year=2010 |pmid=20040833 |doi=10.1097/LGT.0b013e3181ac05e9 |url=}}</ref>


==[[Cervical intraepithelial neoplasia classification|Classification]]==
===Age===
*The median age at diagnosis for cervical intraepithelial neoplasia is 30 years.
*Cervical intraepithelial neoplasia is more commonly seen in women between 20 to 40 years years old.


==[[Cervical intraepithelial neoplasia pathophysiology|Pathophysiology]]==
===Race===
*Hispanic individuals are more likely to develop cervical intraepithelial neoplasia.
*African American individuals are more likely to develop cervical intraepithelial neoplasia.


==[[Cervical intraepithelial neoplasia causes|Causes]]==
==Risk Factors==
*The most important risk factor in the development of cervical intraepithelial neoplasia is [[immunosuppression]].
*Common risk factors in the development of cervical intraepithelial neoplasia, include:<ref name="pmid7942772">{{cite journal |vauthors=Brisson J, Morin C, Fortier M, Roy M, Bouchard C, Leclerc J, Christen A, Guimont C, Penault F, Meisels A |title=Risk factors for cervical intraepithelial neoplasia: differences between low- and high-grade lesions |journal=Am. J. Epidemiol. |volume=140 |issue=8 |pages=700–10 |year=1994 |pmid=7942772 |doi= |url=}}</ref>
:*[[Smoking|Cigarette smoking]]
:*[[Infections]]
::*[[Herpes simplex|Herpes simplex virus]]
::*[[Chlamydia infection|Chlamydia]]
:*[[Chronic inflammatory|Chronic inflammation]] of the cervix
:* [[Oral contraceptives|Use of oral contraceptives]]
:* [[Sexual activity|Increased sexual activity]]
:* Poor socioeconomical status
:* Poor diet<ref name="pmid15912536">{{cite journal |vauthors=García-Closas R, Castellsagué X, Bosch X, González CA |title=The role of diet and nutrition in cervical carcinogenesis: a review of recent evidence |journal=Int. J. Cancer |volume=117 |issue=4 |pages=629–37 |year=2005 |pmid=15912536 |doi=10.1002/ijc.21193 |url=}}</ref>


==[[Cervical intraepithelial neoplasia differential diagnosis|Differentiating Cervical intraepithelial neoplasia from other Diseases]]==
== Natural History, Complications and Prognosis==
*The majority of patients with cervical intraepithelial neoplasia remain [[asymptomatic]] for years.
*Early clinical features include abnormal [[vaginal discharge]], [[dyspareunia]], and abnormal [[vaginal bleeding]].
*If left untreated, 70% patients with cervical intraepithelial neoplasia will regress within one year.
:*90%  of patients with low-grade cervical intraepithelial neoplasia will regress within two years of treatment.
:*50% of patients with high-grade cervical intraepithelial neoplasia will regress within 2 years without treatment.
:*Progression to cervical carcinoma in situ (CIS)
::*11%  of patients low-grade cervical intraepithelial neoplasia will develop CIS.
::*22% of patients high-grade grade cervical intraepithelial neoplasia will develop CIS.
:*Progression to invasive [[cancer]] ([[cervical cancer]])
::* 1% of patients with low-grade cervical intraepithelial neoplasia will develop [[cervical cancer]].
::* 5% - 13% of patients with high-grade grade cervical intraepithelial neoplasia will develop [[cervical cancer]].
*Common complications of cervical intraepithelial neoplasia include [[infertility]], [[Maternal-fetal medicine|maternal-fetal transmission]] of [[human papillomavirus]], and recurrent [[human papillomavirus]] infection.
*[[Prognosis]] is generally good if detected early, and the 5-­year survival rate of patients with high-grade cervical intraepithelial neoplasia is approximately 98%.


==[[Cervical intraepithelial neoplasia epidemiology and demographics|Epidemiology and Demographics]]==
== Diagnosis ==
===Diagnostic Criteria===
*The diagnosis of cervical intraepithelial neoplasia is made with the following histopathological findings:
{| class="wikitable"
! align="center" style="background:#4479BA; color: #FFFFFF;" + | Cytologic findings <br> <SMALL>Lesion grade</SMALL>
! align="center" style="background:#4479BA; color: #FFFFFF;" + | Histologic changes <br><SMALL>Bethesda system</SMALL>
! align="center" style="background:#4479BA; color: #FFFFFF;" + | Description
! align="center" style="background:#4479BA; color: #FFFFFF;" + | Microscopic findings
|-
| '''CIN I'''
Cervical intraepithelial neoplasia I
|
*Low-grade lesion squamous intraepithelial lesion ('''LGSIL''')
|
*Mild [[dysplasia]], or abnormal cell growth
*Presence of [[Koilocyte|koilocytes]]
*Typical cellular changes are usually in the lower third of the [[epithelium]]
| [[Image:Cervical_intraepithelial_neoplasia_(2)_koilocytosis.jpg‎|center|100px]]
|-
| '''CIN II'''
Cervical intraepithelial neoplasia II
|
*High-grade lesion squamous intraepithelial lesion ('''HGSIL''')
|
*Moderate [[dysplasia]]
*Basal two-thirds of the [[epithelium]] is usually involved
*Preservation of [[epithelial]] maturation
| [[Image:100px-Cervical_intraepithelial_neoplasia_(3)_CIN2.jpg‎|center|100px]]
|-
| '''CIN III'''
Cervical intraepithelial neoplasia III
|
*High-grade lesion squamous intraepithelial lesion ('''HGSIL''')
|
*Severe atypical cellular changes
*Greater than two-thirds of the [[epithelial]] thickness is usually involved
*Also known as [[Carcinoma in situ]]
| [[Image:451px-Cervical_intraepithelial_neoplasia_(4)_CIN3.jpg‎|center|100px]]
|}


==[[Cervical intraepithelial neoplasia risk factors|Risk Factors]]==
=== Symptoms ===
*Cervical intraepithelial neoplasia is usually [[asymptomatic]].
*Symptoms of cervical intraepithelial neoplasia may include the following:
:*[[Abdominal pain]]
:*[[Vaginal discharge]] 
:*[[Dyspareunia]]
:*[[Dysmenorrhea]]
:*[[Frequent urination|Polyurea]]
:*[[Leukorrhea]]


==[[Cervical intraepithelial neoplasia screening|Screening]]==
=== Physical Examination ===
*Patients with cervical intraepithelial neoplasia are usually well-appearing.
*Digital examination findings of the [[vagina]] and [[cervix]], may reveal: 
:*Cervical [[Nodular|nodularity]] or hardness of the tissue


==[[Cervical intraepithelial neoplasia natural history|Natural History, Complications and Prognosis]]==
=== Laboratory Findings ===
*Laboratory findings associated with cervical intraepithelial neoplasia, include:
:*[[Human papillomavirus|HPV]] [[DNA]] Testing
===Imaging Findings===
*There are no imaging findings associated with cervical intraepithelial neoplasia.
=== Other Diagnostic Studies ===
*The most important diagnostic study for cervical intraepithelial neoplasia is [[colposcopy]].
*The most common finding of cervical intraepithelial neoplasia in [[colposcopy]] is acetowhite lesions with atypical vessels.
*Other findings on [[vaginal]] [[colposcopy]], include:
:* Greyish-white or yellowish-white lesions
:* Irregular longitudinal [[Blood vessel|vessels]]
::*Corkscrew or tree appearance
:*Cervical nodularity
*The table below summarizes the [[colposcopy]] findings according to the Swede score
{| class="wikitable"
! align="center" style="background:#4479BA; color: #FFFFFF;" + | Swede score for interpreting colposcopy findings
<SMALL> Adapted from Principles and Practice of Colposcopy</SMALL>
|-
|
| style="text-align: center; font-weight: bold;" | 0
| style="text-align: center; font-weight: bold;" | 1
| style="text-align: center; font-weight: bold;" | 2
|-
| style="font-weight: bold;" | Uptake of [[acetic acid]]
| 0 or transparent
| style="text-align: left;" |
*Shady, milky
|
*Distinct, stearin-like
|-
| style="font-weight: bold;" | Margins and surface
| 0 or diffuse
|
*Sharp, but irregular, jagged
*"Geographical" satellites
|
*Sharp and even
*Difference in surface level such as "cutting"
|-
| style="font-weight: bold;" | [[Vessels]]
| Fine, regular
| style="text-align: left;" |
*Absent
|
*Coarse or atypical
|-
| style="font-weight: bold;" | Lesion size
| < 5mm
|
*5-15 mm
*Spanning 2 quadrants
|
*>15mm or spanning
* 3-4 quadrants or endocervically undefined
|-
| style="font-weight: bold;" | Iodine staining
| Brown
|
*Faintly or patchy yellow
|
*Distinct yellow
|-
| colspan="4" | <SMALL>
The total Swede Score ranges between 0 and 10.
A score of  more than 5 is reported to identify all high grade lesions (HGL), and ≥8 to have a specificity of 90% for HGL.
A score less than <5 is suggested to not require [[biopsy]] because of low risk of cancer, a score between 5-7 to require biopsy
A score ≥8 again not to require biopsy because it is likely more efficient to intervene (e.g. excision directly)</SMALL>
|}


==Diagnosis==
===Video===
[[Cervical intraepithelial neoplasia history and symptoms|History and Symptoms]] | [[Cervical intraepithelial neoplasia physical examination|Physical Examination]] | [[Cervical intraepithelial neoplasia staging|Staging]] | [[Cervical intraepithelial neoplasia laboratory tests|Laboratory Findings]] | [[Cervical intraepithelial neoplasia other diagnostic studies|Other Diagnostic Studies]]


==Treatment==
{{#ev:youtube|ekDCA7egnCM}}
[[Cervical intraepithelial neoplasia medical therapy|Medical Therapy]] | [[Cervical intraepithelial neoplasia surgery|Surgery]] | [[Cervical intraepithelial neoplasia primary prevention|Primary Prevention]] | [[Cervical intraepithelial neoplasia secondary prevention|Secondary Prevention]] | [[Cervical intraepithelial neoplasia cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Cervical intraepithelial neoplasia future or investigational therapies|Future or Investigational Therapies]]


==Case Studies==
== Treatment ==
[[Cervical intraepithelial neoplasia case study one|Case Study #1]]
=== Medical Therapy ===
*Medical treatment for cervical intraepithelial neoplasia, include:
:*[[Observation]]
:*Observation is indicated for cervical intraepithelial neoplasia lesions that are:
::*Highly likely to regress
::*High grade lesions associated with a high risk of developing cervical cancer
*The management of cervical intraepithelial neoplasia will depend on patients age:
:*Patients with cervical intraepithelial neoplasia between 21-24 years
:*Patients with cervical intraepithelial neoplasia above 25 years


==Related chapters==
=== Surgery ===
* [[Cervical cancer]]
*[[Surgery]] is the mainstay of therapy for cervical intraepithelial neoplasia.<ref name="pmid10796771">{{cite journal |vauthors=Martin-Hirsch PL, Paraskevaidis E, Kitchener H |title=Surgery for cervical intraepithelial neoplasia |journal=Cochrane Database Syst Rev |volume= |issue=2 |pages=CD001318 |year=2000 |pmid=10796771 |doi=10.1002/14651858.CD001318 |url=}}</ref>
* [[Human papillomavirus]]
*According to the American Society for Colposcopy and Cervical Pathology guidelines, indications for [[Ablation|ablative surgery]] among patients with cervical intraepithelial neoplasia should include:
:*Persistent low-grade cervical intraepithelial neoplasia
:*Cervical intraepithelial neoplasia grade II and grade III
*Common surgical procedures for cervical intraepithelial neoplasia, include:
:*[[Cryocautery]]
:*[[Electrocautery]]
:*[[Laser|Laser cautery]]
:*[[Cervical conization]]
::*Cold knife [[conization]]
::*[[Loop electrical excision procedure|Loop electrical excision]]
*The surgical procedure used depends on the [[histopathological]] lesion grade.
*Cervical [[conization]] can only be performed for patients suspected to have [[Cancer|invasive cancer]].
*Common [[cervical conization]] complications, include:
::*[[Bleeding|Intraoperative bleeding]]
::*[[Uterine rupture|Uterine perforation]]
::*[[Bleeding|Postoperative bleeding]]  
::*[[Infection]]


[[Category:Disease]]
=== Prevention ===
[[Category:Types of cancer]]
*The most effective measure for the [[primary prevention]] of cervical intraepithelial neoplasia is the [[vaccination]] against oncogenic [[human papillomavirus]] ([[HPV]]) infection. 
*The most effective measure for the [[secondary prevention]] of cervical intraepithelial neoplasia is periodic [[Cervical cancer screening|cervical screening]]
*Once diagnosed and successfully treated, patients with cervical intraepithelial neoplasia are followed-up every 3, 6 or 12 months depending on the lesion grade.
*Follow-up testing include periodic screening tests, such as: [[Pap smear|Papanicolaou test]] and [[colposcopy]] examinations.
 
==References==
{{Reflist|2}}
[[Category: Oncology]]
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Gynecology]]
[[Category:Gynecology]]
[[Category:Oncology]]
{{WikiDoc Help Menu}}
{{WS}}

Latest revision as of 11:38, 23 April 2019

For patient information, please click here


WikiDoc Resources for Cervical intraepithelial neoplasia

Articles

Most recent articles on Cervical intraepithelial neoplasia

Most cited articles on Cervical intraepithelial neoplasia

Review articles on Cervical intraepithelial neoplasia

Articles on Cervical intraepithelial neoplasia in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Cervical intraepithelial neoplasia

Images of Cervical intraepithelial neoplasia

Photos of Cervical intraepithelial neoplasia

Podcasts & MP3s on Cervical intraepithelial neoplasia

Videos on Cervical intraepithelial neoplasia

Evidence Based Medicine

Cochrane Collaboration on Cervical intraepithelial neoplasia

Bandolier on Cervical intraepithelial neoplasia

TRIP on Cervical intraepithelial neoplasia

Clinical Trials

Ongoing Trials on Cervical intraepithelial neoplasia at Clinical Trials.gov

Trial results on Cervical intraepithelial neoplasia

Clinical Trials on Cervical intraepithelial neoplasia at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Cervical intraepithelial neoplasia

NICE Guidance on Cervical intraepithelial neoplasia

NHS PRODIGY Guidance

FDA on Cervical intraepithelial neoplasia

CDC on Cervical intraepithelial neoplasia

Books

Books on Cervical intraepithelial neoplasia

News

Cervical intraepithelial neoplasia in the news

Be alerted to news on Cervical intraepithelial neoplasia

News trends on Cervical intraepithelial neoplasia

Commentary

Blogs on Cervical intraepithelial neoplasia

Definitions

Definitions of Cervical intraepithelial neoplasia

Patient Resources / Community

Patient resources on Cervical intraepithelial neoplasia

Discussion groups on Cervical intraepithelial neoplasia

Patient Handouts on Cervical intraepithelial neoplasia

Directions to Hospitals Treating Cervical intraepithelial neoplasia

Risk calculators and risk factors for Cervical intraepithelial neoplasia

Healthcare Provider Resources

Symptoms of Cervical intraepithelial neoplasia

Causes & Risk Factors for Cervical intraepithelial neoplasia

Diagnostic studies for Cervical intraepithelial neoplasia

Treatment of Cervical intraepithelial neoplasia

Continuing Medical Education (CME)

CME Programs on Cervical intraepithelial neoplasia

International

Cervical intraepithelial neoplasia en Espanol

Cervical intraepithelial neoplasia en Francais

Business

Cervical intraepithelial neoplasia in the Marketplace

Patents on Cervical intraepithelial neoplasia

Experimental / Informatics

List of terms related to Cervical intraepithelial neoplasia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]

Synonyms and keywords: CIN; Cervical interstitial neoplasia; Cervical dysplasia; Cervical interstitial neoplasia

Overview

Cervical intraepithelial neoplasia (also known as cervical dysplasia and CIN), is the potentially premalignant transformation and abnormal growth (dysplasia) of squamous cells on the surface of the cervix. Cervical intraepithelial neoplasia was first discovered by Dr. Georgios Nikolaou Papanikolaou, a Greek pathologist, in 1927. There are 4 cytological classifications for cervical intraepithelial neoplasia: Bethesda system, Papanicolaou classification, CIN nomenclature, and dysplasia nomenclature. The most common cytological classification systems for cervical intraepithelial neoplasia is the Bethesda and CIN nomenclature. Cervical intraepithelial neoplasia may be classified according to Bethesda system by cytology description into 3 subtypes: atypical squamous cells, low grade squamous intraepithelial lesion (LGSIL or LSIL), and high grade squamous intraepithelial lesion (HGSIL or HSIL). The pathogenesis of cervical intraepithelial neoplasia is characterized by the premalignant transformation and abnormal growth of squamous cells on the surface of the cervix. The presence of human papillomavirus (HPV) has a crucial role in the pathogenesis of cervical intraepithelial neoplasia. The infection of human papillomavirus (HPV) leads to the first precursor lesion of cervical intraepithelial neoplasia, also known as the koilocyte, which is a squamous epithelial cell that has undergone a number of structural changes. Surgery is the mainstay of therapy for cervical intraepithelial neoplasia. According to the American Society for Colposcopy and Cervical Pathology guidelines, indications for ablative surgery among patients with cervical intraepithelial neoplasia should include: persistent low-grade cervical intraepithelial neoplasia, cervical intraepithelial neoplasia grade II and grade III. Common surgical procedures for cervical intraepithelial neoplasia, include cryocautery, electrocautery, laser cautery, and cervical conization.

Historical Perspective

  • Cervical intraepithelial neoplasia was first discovered by Dr. Georgios Nikolaou Papanikolaou, a Greek pathologist, in 1927.[1]
  • In 1928, the first screening was developed by Aurel Babeș, a Romanian pathologist to diagnose cervical intraepithelial neoplasia.[1]
  • In 1980, human papillomavirus (HPV) was first identified in the pathogenesis of cervical intraepithelial neoplasia.[2]
  • In 1988, the Bethesda system classification method was introduced to categorize histopathological findings of cervical intraepithelial neoplasia according to degrees of severity.

Classification

  • Cervical intraepithelial neoplasia has 4 cytological classifications: Bethesda system, Papanicolaou classification, CIN nomenclature, and dysplasia nomenclature.
  • The most common classification systems for cervical intraepithelial neoplasia is the Bethesda and CIN nomenclature.
  • Cervical intraepithelial neoplasia may be classified according to Bethesda system by cytology description into 3 subtypes:
  • Undetermined significance (ASC-US)
  • Low grade squamous intraepithelial lesion (LGSIL or LSIL)
  • High grade squamous intraepithelial lesion (HGSIL or HSIL)
  • Cervical intraepithelial neoplasia may be classified according to CIN nomenclature by histological severity into 3 subtypes:
  • Cervical intraepithelial neoplasia I (CIN I)
  • Cervical intraepithelial neoplasia II (CIN II)
  • Cervical intraepithelial neoplasia III (CIN III)
  • Cervical intraepithelial neoplasia may be classified according to Papanicolau by cytology description into 5 subtypes:
  • Cervical intraepithelial neoplasia may be classified according to dysplasia nomenclature by cytology description into 5 subtypes:

Pathophysiology

Cytologic findings
Lesion grade
Histologic changes
Bethesda system
Description Microscopic findings
CIN I

Cervical intraepithelial neoplasia I

  • Low-grade lesion squamous intraepithelial lesion (LGSIL)
CIN II

Cervical intraepithelial neoplasia II

  • High-grade lesion squamous intraepithelial lesion (HGSIL)
CIN III

Cervical intraepithelial neoplasia III

  • High-grade lesion squamous intraepithelial lesion (HGSIL)
  • Severe atypical cellular changes
  • Greater than two-thirds of the epithelial thickness is usually involved
  • Also known as Carcinoma in situ

Molecular Pathogenesis

Causes

  • Subtypes 16,18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 69, 82
  • Subtypes 6, 11, 40, 42, 43, 44, 54, 61, 72, 81

Differentiating Cervical Intraepithelial Neoplasia from Other Diseases

Epidemiology and Demographics

Prevalence

  • The prevalence of cervical intraepithelial neoplasia I (CIN I) is approximately 54 cases per 100,000 individuals in the United States.[7]
  • The prevalence of cervical intraepithelial neoplasia II (CIN II) is approximately 255 cases per 100,000 individuals in the United States.[7]
  • The prevalence of cervical intraepithelial neoplasia III (CIN III) is approximately 141 cases per 100,000 individuals in the United States.[7]
  • The prevalence of invasive carcinoma is approximately 24 cases per 100,000 individuals in the United States.[7]

Incidence

  • The incidence of cervical intraepithelial neoplasia I (CIN I) is 160 cases per 100,000 individuals per year in the United States.[8]
  • The incidence of cervical intraepithelial neoplasia II (CIN II) is 120 cases per 100,000 individuals per year in the United States.[8]

Age

  • The median age at diagnosis for cervical intraepithelial neoplasia is 30 years.
  • Cervical intraepithelial neoplasia is more commonly seen in women between 20 to 40 years years old.

Race

  • Hispanic individuals are more likely to develop cervical intraepithelial neoplasia.
  • African American individuals are more likely to develop cervical intraepithelial neoplasia.

Risk Factors

  • The most important risk factor in the development of cervical intraepithelial neoplasia is immunosuppression.
  • Common risk factors in the development of cervical intraepithelial neoplasia, include:[9]

Natural History, Complications and Prognosis

  • The majority of patients with cervical intraepithelial neoplasia remain asymptomatic for years.
  • Early clinical features include abnormal vaginal discharge, dyspareunia, and abnormal vaginal bleeding.
  • If left untreated, 70% patients with cervical intraepithelial neoplasia will regress within one year.
  • 90% of patients with low-grade cervical intraepithelial neoplasia will regress within two years of treatment.
  • 50% of patients with high-grade cervical intraepithelial neoplasia will regress within 2 years without treatment.
  • Progression to cervical carcinoma in situ (CIS)
  • 11% of patients low-grade cervical intraepithelial neoplasia will develop CIS.
  • 22% of patients high-grade grade cervical intraepithelial neoplasia will develop CIS.
  • 1% of patients with low-grade cervical intraepithelial neoplasia will develop cervical cancer.
  • 5% - 13% of patients with high-grade grade cervical intraepithelial neoplasia will develop cervical cancer.

Diagnosis

Diagnostic Criteria

  • The diagnosis of cervical intraepithelial neoplasia is made with the following histopathological findings:
Cytologic findings
Lesion grade
Histologic changes
Bethesda system
Description Microscopic findings
CIN I

Cervical intraepithelial neoplasia I

  • Low-grade lesion squamous intraepithelial lesion (LGSIL)
CIN II

Cervical intraepithelial neoplasia II

  • High-grade lesion squamous intraepithelial lesion (HGSIL)
CIN III

Cervical intraepithelial neoplasia III

  • High-grade lesion squamous intraepithelial lesion (HGSIL)
  • Severe atypical cellular changes
  • Greater than two-thirds of the epithelial thickness is usually involved
  • Also known as Carcinoma in situ

Symptoms

  • Cervical intraepithelial neoplasia is usually asymptomatic.
  • Symptoms of cervical intraepithelial neoplasia may include the following:

Physical Examination

  • Patients with cervical intraepithelial neoplasia are usually well-appearing.
  • Digital examination findings of the vagina and cervix, may reveal:

Laboratory Findings

  • Laboratory findings associated with cervical intraepithelial neoplasia, include:

Imaging Findings

  • There are no imaging findings associated with cervical intraepithelial neoplasia.

Other Diagnostic Studies

  • The most important diagnostic study for cervical intraepithelial neoplasia is colposcopy.
  • The most common finding of cervical intraepithelial neoplasia in colposcopy is acetowhite lesions with atypical vessels.
  • Other findings on vaginal colposcopy, include:
  • Greyish-white or yellowish-white lesions
  • Irregular longitudinal vessels
  • Corkscrew or tree appearance
  • Cervical nodularity
  • The table below summarizes the colposcopy findings according to the Swede score
Swede score for interpreting colposcopy findings

Adapted from Principles and Practice of Colposcopy

0 1 2
Uptake of acetic acid 0 or transparent
  • Shady, milky
  • Distinct, stearin-like
Margins and surface 0 or diffuse
  • Sharp, but irregular, jagged
  • "Geographical" satellites
  • Sharp and even
  • Difference in surface level such as "cutting"
Vessels Fine, regular
  • Absent
  • Coarse or atypical
Lesion size < 5mm
  • 5-15 mm
  • Spanning 2 quadrants
  • >15mm or spanning
  • 3-4 quadrants or endocervically undefined
Iodine staining Brown
  • Faintly or patchy yellow
  • Distinct yellow

The total Swede Score ranges between 0 and 10. A score of more than 5 is reported to identify all high grade lesions (HGL), and ≥8 to have a specificity of 90% for HGL. A score less than <5 is suggested to not require biopsy because of low risk of cancer, a score between 5-7 to require biopsy A score ≥8 again not to require biopsy because it is likely more efficient to intervene (e.g. excision directly)

Video

{{#ev:youtube|ekDCA7egnCM}}

Treatment

Medical Therapy

  • Medical treatment for cervical intraepithelial neoplasia, include:
  • Observation
  • Observation is indicated for cervical intraepithelial neoplasia lesions that are:
  • Highly likely to regress
  • High grade lesions associated with a high risk of developing cervical cancer
  • The management of cervical intraepithelial neoplasia will depend on patients age:
  • Patients with cervical intraepithelial neoplasia between 21-24 years
  • Patients with cervical intraepithelial neoplasia above 25 years

Surgery

  • Surgery is the mainstay of therapy for cervical intraepithelial neoplasia.[11]
  • According to the American Society for Colposcopy and Cervical Pathology guidelines, indications for ablative surgery among patients with cervical intraepithelial neoplasia should include:
  • Persistent low-grade cervical intraepithelial neoplasia
  • Cervical intraepithelial neoplasia grade II and grade III
  • Common surgical procedures for cervical intraepithelial neoplasia, include:

Prevention

References

  1. 1.0 1.1 Georgios Nikolaou Papanikolaou Wikipedia. https://en.wikipedia.org/wiki/Georgios_Papanikolaou Accessed on March 29, 2016
  2. Herfs M, Crum CP (2013). "Laboratory management of cervical intraepithelial neoplasia: proposing a new paradigm". Adv Anat Pathol. 20 (2): 86–94. doi:10.1097/PAP.0b013e3182862aab. PMID 23399794.
  3. Arends MJ, Buckley CH, Wells M (1998). "Aetiology, pathogenesis, and pathology of cervical neoplasia". J. Clin. Pathol. 51 (2): 96–103. PMC 500501. PMID 9602680.
  4. Braaten KP, Laufer MR (2008). "Human Papillomavirus (HPV), HPV-Related Disease, and the HPV Vaccine". Rev Obstet Gynecol. 1 (1): 2–10. PMC 2492590. PMID 18701931.
  5. Skinner SR, Wheeler CM, Romanowski B, Castellsagué X, Lazcano-Ponce E, Del Rosario-Raymundo MR, Vallejos C, Minkina G, Pereira Da Silva D, McNeil S, Prilepskaya V, Gogotadze I, Money D, Garland SM, Romanenko V, Harper DM, Levin MJ, Chatterjee A, Geeraerts B, Struyf F, Dubin G, Bozonnat MC, Rosillon D, Baril L (May 2016). "Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study". Int. J. Cancer. 138 (10): 2428–38. doi:10.1002/ijc.29971. PMC 4787275. PMID 26685704.
  6. Krawczyk E, Suprynowicz FA, Liu X, Dai Y, Hartmann DP, Hanover J, Schlegel R (September 2008). "Koilocytosis: a cooperative interaction between the human papillomavirus E5 and E6 oncoproteins". Am. J. Pathol. 173 (3): 682–8. doi:10.2353/ajpath.2008.080280. PMC 2527066. PMID 18688031.
  7. 7.0 7.1 7.2 7.3 Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE (2007). "Prevalence of HPV infection among females in the United States". JAMA. 297 (8): 813–9. doi:10.1001/jama.297.8.813. PMID 17327523.
  8. 8.0 8.1 Henk HJ, Insinga RP, Singhal PK, Darkow T (2010). "Incidence and costs of cervical intraepithelial neoplasia in a US commercially insured population". J Low Genit Tract Dis. 14 (1): 29–36. doi:10.1097/LGT.0b013e3181ac05e9. PMID 20040833.
  9. Brisson J, Morin C, Fortier M, Roy M, Bouchard C, Leclerc J, Christen A, Guimont C, Penault F, Meisels A (1994). "Risk factors for cervical intraepithelial neoplasia: differences between low- and high-grade lesions". Am. J. Epidemiol. 140 (8): 700–10. PMID 7942772.
  10. García-Closas R, Castellsagué X, Bosch X, González CA (2005). "The role of diet and nutrition in cervical carcinogenesis: a review of recent evidence". Int. J. Cancer. 117 (4): 629–37. doi:10.1002/ijc.21193. PMID 15912536.
  11. Martin-Hirsch PL, Paraskevaidis E, Kitchener H (2000). "Surgery for cervical intraepithelial neoplasia". Cochrane Database Syst Rev (2): CD001318. doi:10.1002/14651858.CD001318. PMID 10796771.